Spyros Papapetropoulos - Jun 2, 2021 Form 4 Insider Report for Adamas Pharmaceuticals Inc (ADMS)

Role: Director
Signature: /s/ Christopher Prentiss, Attorney-in-fact
Stock symbol: ADMS
Transactions as of: Jun 2, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/4/2021, 04:16 PM
Next filing: Nov 24, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADMS	Common Stock	Award	$0	+5K	+31.3%	$0.00	21K	Jun 2, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADMS	Stock Option (Right to Buy)	Award	$0	+10K		$0.00	10K	Jun 2, 2021	Common Stock	10K	$5.21	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.
F2	The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.